Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

492.42
+1.950.40%
Volume:1.25M
Turnover:613.93M
Market Cap:126.59B
PE:-236.74
High:498.41
Open:488.27
Low:484.97
Close:490.47
Loading ...

3 Magnificent Growth Stocks to Buy in March

Motley Fool
·
08 Mar

Sector Update: Health Care Stocks Higher Friday Afternoon

MT Newswires Live
·
08 Mar

Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment

Simply Wall St.
·
08 Mar

BRIEF-Vertex Announces UK Mhra Approval Of Alyftrek

Reuters
·
08 Mar

Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis

MT Newswires Live
·
07 Mar

Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF

TIPRANKS
·
07 Mar

Vertex Pharmaceuticals Inc - Working With Nice and Nhs for Alyftrek Access

THOMSON REUTERS
·
07 Mar

Vertex Announces UK Mhra Approval of Alyftrek® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class Cftr Modulator for the Treatment of Cystic Fibrosis

THOMSON REUTERS
·
07 Mar

Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

Business Wire
·
07 Mar

Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK

MT Newswires Live
·
07 Mar

BRIEF-UK's MHRA Approves Triple Combination Of Deutivacaftor/Tezacaftor/Vanzacaftor For Cystic Fibrosis

Reuters
·
07 Mar

UK's Mhra Says Triple Combination Medicine Deutivacaftor/Tezacaftor/Vanzacaftor Approved for Cystic Fibrosis

THOMSON REUTERS
·
07 Mar

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
07 Mar

3 Stocks Estimated To Be Up To 49.3% Below Their Intrinsic Value

Simply Wall St.
·
07 Mar

BUZZ-Status of Vertex's painkiller on UnitedHealth lists poses modest challenge, BMO says

Reuters
·
07 Mar

Vertex non-opioid pain drug picked up by UnitedHealth

TIPRANKS
·
07 Mar

Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary

MT Newswires Live
·
07 Mar

Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
06 Mar

Vertex Pharmaceuticals Inc. Stock Rises Wednesday, Still Underperforms Market

Dow Jones
·
06 Mar

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

GlobeNewswire
·
06 Mar